Pharma Focus Asia

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6

Saturday, June 17, 2023

TG ImmunoPharma announced the FDA clearance for the clinical trial of TGI-6. This antibody is designed to target unique tumour-associated antigens (TAA) and CD3 molecules, resulting in effective antitumor responses.

TGI-6 has demonstrated exceptional anti-tumour activity and possesses favourable safety profiles, along with remarkable druggability. The TAA (Tumour-Associated Antigen) targeted by TGI-6, is known to be highly expressed in several solid tumours. These tumours include colourectal cancer, breast cancer, hepatocellular carcinoma (liver cancer), gastric cancer, ovarian cancer, pancreatic cancer, and potentially other types as well.

TGI-6 is designed to maintain high cytotoxic activity against cancer cells while minimising the risk of cytokine release syndrome (CRS), a potentially harmful immune response. This feature enhances the safety and therapeutic potential of TGI-6.

TGI remains steadfast in its mission to transform cancer care through innovative immunotherapies. The FDA's approval of the TGI-6 clinical trial is expected to propel the progress of precision therapies for solid tumours. 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024